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The early mammalian embryo is characterized by the presence of three germ layers-the
outer ectoderm, middle mesoderm and inner endoderm. The mesoderm is organized
into paraxial, intermediate and lateral plate mesoderm. The musculature, vasculature
and heart of the adult body are the major derivatives of mesoderm. Tracing back the
developmental process to generate these specialized tissues has sparked much interest
in the field of regenerative medicine focusing on generating specialized tissues to treat
patients with degenerative diseases. Several Long Non-Coding RNAs (lncRNAs) have
been identified as regulators of development, proliferation and differentiation of various
tissues of mesodermal origin. A better understanding of lncRNAs that can regulate
the development of these tissues will open potential avenues for their therapeutic
utility and enhance our knowledge about disease progression and development. In this
review, we aim to summarize the functions and mechanisms of lncRNAs regulating the
early mesoderm differentiation, development and homeostasis of skeletal muscle and
cardiovascular system with an emphasis on their therapeutic potential.
Keywords: non-coding RNA, skeletal muscle, endothelial cell, vascular smooth muscle cell (VSMC),
differentiation, mesoderm, myogenesis, cardiovascular diseases
INTRODUCTION
Gastrulation results in the formation of the three germ layers - ectoderm, mesoderm and
endoderm. The mesoderm is a middle layer between the innermost, endoderm and the outer
ectoderm. The transition from epithelial cells to mesenchymal cells marks the formation of
mesoderm which is further organized into the paraxial, intermediate and lateral mesoderm
(Nakaya and Sheng, 2008; Evseenko et al., 2010). The three parts of the mesoderm are acted upon
by several lineage commitment programs and differentiate into the progenitor cells that give rise
to musculoskeletal, urogenital and cardiovascular structures of the body (Doss et al., 2012). Cells
of these organs have the same genome, but the differences in transcriptionally active and inactive
regions of genome guide the precursor cells toward different cell fates (Iwafuchi-Doi and Zaret,
2016). The differences in genomic organization, followed by activation or silencing of genes, are the
result of complex gene regulatory networks (GRNs) (Materna and Davidson, 2007). For many years
these GRNs were thought to be controlled exclusively by protein coding genes until the discovery
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of functional non-coding RNA transcripts (ncRNAs) which form
an integrated network to shape the cellular environment during
different developmental and metabolic processes (Kim and Sung,
2012). These ncRNAs are divided into two categories based
on the transcript length—small ncRNAs (<200 nucleotides)
and long ncRNAs (>200 nucleotides) (Mercer et al., 2009).
Currently, miRNAs are the best-characterized ncRNAs that are
well conserved and repress the expression of target mRNA by
binding to its 3′ UTR (Majoros and Ohler, 2007). On the other
hand, long ncRNAs (lncRNAs) constitute a less characterized
but highly diverse class of ncRNAs. lncRNAs are structurally
similar to protein-coding genes as most of them are transcribed
by RNA polymerase II, 5′ capped and polyadenylated at 3′
end (Bunch et al., 2016). Regardless of their close similarity
to the protein-coding mRNAs, lncRNAs lack the potential to
code functional proteins. Although there are many lncRNAs that
contain putative open reading frames and indeed some have
been re-classified to protein-coding genes (Anderson et al., 2015;
Nelson et al., 2016; Matsumoto et al., 2017). The number of
bona-fide lncRNAs identified in human genome is, in general,
comparable to that of protein-coding genes, but only a few
have been functionally characterized. Functionally, lncRNAs can
either act in cis by regulating expression of neighboring genes,
or in trans, regulating the expression of distant genes (Ulitsky
and Bartel, 2013). lncRNAs regulate the gene expression by
mending the 3-dimentional genome organization, mediating the
binding of chromatin modifying proteins or by sequestering the
bound regulatory factors or miRNAs by acting as molecular
decoys or sponge (Morriss and Cooper, 2017). A summary of
different mechanisms of lncRNA mediated genome regulation is
represented in Figure 1. A further class of lncRNAs emerging
from regulatory regions of the genome such as enhancers can
initiate chromatin looping by recruiting chromatin modifying
factors to activate or repress transcription at distant genomic
location (Wang et al., 2011). In the past decade several
research groups have speculated on the functions of lncRNAs in
different biological and pathological systems. More specifically,
many lncRNAs have been reported to play crucial roles in
the development of skeletal muscle and cardiac lineages, and
connected diseases. Here, we discuss the current understanding
of the roles of lncRNAs in skeletal muscle and cardiac derivatives
emphasizing on their therapeutic potential in the associated
pathological conditions.
lncRNAs DURING EARLY MESODERMAL
SPECIFICATION
Recent studies suggest that lncRNAs are important for
mesodermal specification and further differentiation,
development and function of mesodermal derivatives (Figure 2).
For instance, antisense RNA Evx1as regulates mesendodermal
differentiation toward the mesoderm/posterior streak fate
through cis regulation of Even-skipped homeobox 1 (Evx1) (Luo
et al., 2016). Evx1 is a homeodomain TF that promotes mesoderm
differentiation by inhibiting the endoderm/anterior streak gene
GSC (Kalisz et al., 2012). The expression of the divergent lncRNA
Evx1as was highly correlated with the expression of Evx1.
Interestingly, Evx1as knockdown exhibited a higher impact on
the expression of mesendoderm markers than the knockdown
of Evx1, suggesting the possible trans regulation by Evx1as
independent of Evx1 (Luo et al., 2016). lncRNA HoxBlinc is
involved in early differentiation and is transcribed from the
Homeobox B (Hoxb) locus marking the formation of Flk+
mesoderm with the potential to form hematopoietic and cardiac
cells (Deng et al., 2016). As in the case of Evx1as and HoxBlinc,
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FIGURE 1 | lncRNA mechanisms of action. (A) Guide lncRNAs activate or repress gene expression through relocalization of regulatory factors. (B) Scaffold lncRNAs
aid in the formation of Ribonucleoprotein (RNP) complexes. (C) Decoy lncRNAs remove the regulatory factor bound to the genome thereby terminating its regulation.
(D) lncRNAs sponge the miRNAs, thus inhibiting the miRNA mediated gene repression. (E) miRNA precursor lncRNAs function as primary miRNA precursors that
are processed into mature miRNAs. (F) lncRNA transcription from regulatory regions of the genome initiate long range gene regulation.
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FIGURE 2 | lncRNAs expressed during early development of mesoderm and
further differentiation towards skeletal muscle and cardiac lineages.
genomic loci of many other key developmental regulators were
found to transcribe divergent lncRNAs, collectively termed as
Ying Yang lncRNAs (yylncRNAs). Ying Yang lncRNAs follow
tissue-specific expression patterns similar to that of their
protein-coding counterparts (Frank et al., 2019). The active
locus of the mesoderm specifier BRACHUARY (T) encodes
yylncT and the expression patterns of the two were nearly
identical during mesodermal commitment. The depletion
of yylncT specifically abolished the differentiation of human
embryonic stem cells (hESCs) to mesoderm without affecting the
differentiation toward ectoderm and endoderm, emphasizing the
mesoderm specific role of yylncT (Frank et al., 2019). A summary
of lncRNAs regulating early mesodermal differentiation is
illustrated in Figure 2.
lncRNAs REGULATING MYOBLAST
PROLIFERATION AND MUSCLE
DEVELOPMENT
During embryonic development, the paraxial mesoderm
develops into segmented somites, organized into ventral
sclerotome and dorsal dermomyotome which form the axial
skeleton, the skeletal muscle and the dermis of the adult body,
respectively (Chal and Pourquié, 2017). Myogenic progenitor
cells (MPCs) are formed in the myotome and subsequently
become myoblasts that proliferate and differentiate to form
myotubes maturing into skeletal muscle fibers. The MPCs are
also responsible for the formation of quiescent satellite cells that
contribute to regeneration in adult muscles (Chal and Pourquié,
2017). Upon injury, satellite cells in the adult body get activated
and become proliferative myoblasts further differentiating to
form new muscle fibers. Alterations in regulatory circuitry of
myogenesis leads to muscle disorders and diseases such as,
hypertrophy and atrophy. This makes it advantageous to identify
novel molecular regulators of myogenesis and injury induced
regeneration which will aid to discern new therapeutic targets.
Before differentiating into mature myofibers, the myoblasts
proliferate with the activation of cell cycle genes. lncRNA Sirt1AS
is an antisense RNA that promotes myoblast proliferation by
protecting Sirt1 mRNA—a suppressor of cell cycle inhibitors—
from miR-34a mediated degradation (Wang G.-Q. et al., 2016).
lnc-31 also promotes proliferation by maintaining the expression
of critical cell cycle genes, cyclin D1 (Ccnd1), cyclin E (Ccne1)
and Cdc25a (Ballarino et al., 2015). lnc-31 harbors miR-31
precursor sequence, but works independently of miR-31. Despite
the poor sequence conservation, both lnc-31 and its human
homologue, has-lnc-31, are upregulated during proliferation
antagonizing the differentiation process. Furthermore, lnc-31
and has-lnc-31 are abundantly expressed in Duchenne muscular
dystrophy (DMD) in mice and humans (Ballarino et al., 2015).
Recently, lncRNA Syisl was reported to supress myoblast
differentiation, promoting cell proliferation and fusion. Syisl
escorts the EZH2 of PRC2 to the promoter of cell cycle
inhibitor p21 and core myogenic genes like MyoG, Mck,
Myh4 (Jin et al., 2018). The same study reported increase
in muscle density upon in vivo knockout of Syisl. lncRNA
Syisl presents an example of lncRNAs activated in a stage
specific manner in regulation of early myogenesis. A schematic
representation of lncRNAs regulating the early and late phases of
myogenesis with their downstream and upstream effector targets
is provided in Figure 3.
lncRNAs REGULATING MYOBLAST
DIFFERENTIATION
Myoblast differentiation leads to the formation of multinucleate
myotubes that form the mature myofiber (Chal and Pourquié,
2017). A number of stage specific factors, such as MyoD, Myf5,
MyoG, and MRF4 act in coordination with epigenetic and
transcriptional regulators to regulate the myoblast differentiation
(Braun and Gautel, 2011). Enhancer regions of MyoD and MyoG
were shown to give rise to eRNAs (enhancer RNAs) which in turn
regulate their expression. Two such examples are core enhancer
eRNA (CEeRNA) and MUNC – both of which are transcribed
from the upstream regulatory region of MyoD (Mousavi et al.,
2013). CEeRNA is transcribed from the core enhancer of MyoD
regulating its expression in cis by facilitating the chromatin
accessibility to RNA polymerase ll. Whereas, MUNC (also called
as DRRRNA) is transcribed from Distal Regulatory Region (DRR)
of MyoD, enhances the expression of MyoD in cis and of distantly
located myogenic genes, MyoG and Myh3, in trans (Mueller et al.,
2015). Albeit MUNC overlaps the DRR of MyoD, MUNC acts
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FIGURE 3 | lncRNAs regulate myogenesis at different stages. During myogenesis, myoblast cells proliferate and differentiate into myocytes that fuse together to
form multinucleate myotubes. The proliferative and differentiation stages of myogenesis are regulated by several lncRNAs. (A) lncRNAs regulating the myoblast
proliferation by activating downstream cell cycle genes. (B) lncRNAs expression and function during cell cycle exit and differentiation to form myotubes. (C) MyoD
activated lncRNAs regulate other myogenic factors including MyoD and MyoG to form a complex MyoD–lncRNA–miRNA–mRNA regulatory network during
differentiation of myoblasts. (D) Examples of lncRNA expressed and regulating various skeletal muscle disorders.
on multiple myogenic gene promoters. Similar to eRNAs, the
promoter region of mouse and human MyoG transcribes lncRNA
Myoparr essential for cell cycle withdrawal by activating multiple
myogenic factors including the neighboring TF MyoG (Hitachi
et al., 2019). Myoparr regulates the interaction between MyoD
coactivator Ddx17 and histone acetyl transferase and promotes
denervation caused atrophy (Hitachi et al., 2019). The discovery
of eRNAs and promoter associated RNAs highlight an additional
role of regulatory regions of genome, such as enhancers, in
genome regulation.
lncRNA and mRNA microarray analysis identified 997
differentially expressed lncRNAs upon MyoD knockdown in
C2C12 cells (Guo et al., 2017). Gene ontology predicted that
most of these lncRNAs are associated with pathways involved
in muscle formation and cell cycle regulation. The study also
identified lncRNA-AK143003 to be significantly regulated by
MyoD. In silencing and overexpression experiments AK143003
acts as differentiation antagonist, but further investigation is
required to assess its role and mechanism during myogenesis.
This study provides a repertoire of lncRNAs in MyoD network
for further validation. Another lncRNA involving MyoD in
the regulatory circuitry is linc-RAM (Linc-RNA Activator of
Myogenesis). It binds to MyoD and facilitates the assemblage
of MyoD-Baf60c–Brg1 complex onto the regulatory regions of
myogenic genes (Yu et al., 2017). In addition, lncRNA SRA acts
as a coactivator for master regulator of muscle differentiation,
MyoD and SRA Knockdown prevented proper expression of
muscle genes and differentiation (Caretti et al., 2006). Taken
together, these lncRNAs present a second layer of regulation in
the MyoD regulatory network. Figure 3C, depicts an overview of
MyoD regulated lncRNAs and in turn the lncRNAs modulating
MyoD and other myogenic genes.
lncRNAs are known to act as guides and scaffolds by recruiting
chromatin or DNA modifying complexes. DUM silences Dppa2,
an anti-myogenic regulator, by recruiting Dnmts to CpG sites
of Dppa2 promoter (Wang L. et al., 2015). Dum acts as a
promyogenic factor transcriptionally induced by MyoD with
highest expression during proliferation and early myogenesis.
Ectopic overexpression of DUM improved regeneration of
muscle mass (Wang L. et al., 2015). lncMyoD is another lncRNA
activated by MyoD in terminal muscle differentiation suppressing
the IGF2-mRNA-binding protein 2 (IMP2) mediated translation
of proliferation genes (Gong et al., 2015).
The maternally imprinted lncRNA H19 is expressed
exclusively in embryonic tissues and strongly repressed
after birth in all tissue types but skeletal muscles (Brannan
et al., 1990; Poirier et al., 1991). H19 knockdown decreased
the differentiation of myoblast cells and mouse satellite cells by
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derepressing the mRNAs targets of miR-675-3p and miR-675-
5p, encoded by H19, emphasizing a crucial role of H19 during
skeletal muscle differentiation (Dey et al., 2014). During myoblast
differentiation, miR-675-3p downregulated the BMP pathway
by targeting anti-differentiation smad1 and smad5, whereas
miR-675-5p repressed the DNA replication initiation factor Cdc6
(Dey et al., 2014). Another study suggests that H19 decrease
the expression of myoblast inhibitory genes Sirt1/FoxO1, thus
reinforcing the role of H19 in muscle differentiation (Xu et al.,
2017). In addition, H19 has been shown to act as a molecular
sponge for microRNAs belonging to let-7 family, preventing
premature myoblast differentiation (Kallen et al., 2013). More
recently, a study of double mutant mice lacking MyoD and Igf2
genes elucidates a complex loop of H19 mediated Igf2 repression
by MyoD in development of diaphragm muscle (Borensztein
et al., 2013). The authors demonstrate that MyoD stabilized the
interaction of CS9 mesodermal enhancer with H19 promoter
that accounts for increased expression of H19 in the presence
of MyoD. Furthermore, H19 represses Igf2 expression in trans
(Wilkin et al., 2000). MyoD is in turn negatively regulated due to
downregulation of SRF by Igf2 encoded miR-483. Conclusively,
H19-Igf2-MyoD are tightly regulated in a negative feedback loop
during embryonic myogenesis (Qiao et al., 2011; Borensztein
et al., 2013). Overall, it appears that H19 has a crucial role in
myoblast differentiation by mechanistically regulating the key
genes such as IGF-2, Sirt1/FoxO1, and microRNAs miR-675 and
let-7 during adult as well as embryonic myogenesis.
Similar to H19, lncRNA MALAT1 targets multiple factors
during myogenesis. Malat1 is incessantly upregulated during the
differentiation of myoblasts to myotubes and its downregulation
results in cell cycle arrest in G0/G1 phase, suppressing myoblast
proliferation (Watts et al., 2013). A recent study demonstrated
a new mechanism of microRNA mediated degradation of
MALAT1 transcripts in myoblast nucleus by miR-181 through
Ago2-dependent nuclear RNA-induced silencing complex (RISC)
(Chen et al., 2017). MALAT1 was also found to influence miR-
133 mediated SRF targeting during myogenesis (Han et al., 2015).
Conclusively, these mechanistic studies provide evidence that a
single lncRNA can act at different levels in GRN through multiple
of modes of action.
As seen in H19 and MALAT1, sponging of miRNA appears
to be a common mechanism of lncRNA action in muscle
differentiation. For instance, lnc-mg (myogenesis associated
lncRNA) promoted Igf2 mediated myogenesis by titrating miR-
125b (Zhu et al., 2017). lnc-mg was enriched in skeletal
muscle and its silencing caused muscle atrophy and loss of
muscular endurance during exercise and its overexpression led
to hypertrophy. Furthermore, its expression was dynamically
induced during differentiation of muscle stem cells (Zhu et al.,
2017). Similarly, linc-MD1 modulates the time of muscle
differentiation by favoring the expression of MAML1 and MEF2C
by sponging miR-133 and miR-135, respectively (Cesana et al.,
2011). In addition to sponging of miR-133, linc-MD1 is also
the host of miR-133 enabling its alternate synthesize from linc-
MD1, controlled by a feedforward positive loop of HuR protein
and linc-MD1 (Legnini et al., 2014). linc-MD1 sponges miR-
133b derepressing the expression of HuR protein which in turn
physically interacts with linc-MD1 to prevent Drosha cleavage of
pri-miR-133 sequence (Legnini et al., 2014).
TF Yin Yang 1 (YY1) is an important regulator of myogenesis
that silences multiple genes in myoblasts by recruiting Ezh2
(Enhancer of ZesteHomologue2) (Caretti et al., 2004; Wang
et al., 2007). Promoter region of YY1 gives rise to linc-YY1
exhibiting low expression in proliferating myoblasts, increased at
the beginning of the myogenic program with gradual decrease in
the late stages of myogenesis (Zhou et al., 2015). Interestingly,
YY1 follows a similar expression profile during the process.
When myoblasts undergo differentiation, linc-YY1 is activated by
MyoD, which then destabilizes the YY1/PRC2 complex activating
pro-differentiation genes (Zhou et al., 2015). Knockdown of linc-
YY1 delayed the expression of many myogenic markers which
are direct targets of YY1/PRC2, such as MyoG, MyHC, Tnni2
and a-Actin, and miR-1 and miR-29. This indicates that linc-
YY1 is a pro-myogenic factor whose knockdown in C2C12
cells delayed myogenic differentiation. Genome wide ChIP-
Seq in myoblasts revealed that YY1 regulates several lincRNAs
in skeletal muscle collectively called as Yams (YY1-associated
muscle lincRNAs) (Lu et al., 2013). Yam1 is a lncRNA regulated
by YY1 and acts as an anti-myogenic factor and exerts its function
in cis through regulation of miR-715 and via targeting Wnt7b
expression (Lu et al., 2013). Downregulation of Wnt7b inhibits
myogenic differentiation (von Maltzahn et al., 2012). Among
other Yams, Yam-3 also inhibits differentiation while, Yam-2 and
Yam-4 facilitates early differentiation (Lu et al., 2013). These
observations indicate that lncRNAs are not only regulated by
key TFs but in turn regulate the function of other TFs. A list of
lncRNAs regulating myogenesis is represented in Table 1.
THERAPEUTIC POTENTIAL OF lncRNAs
IN MUSCLE REGENERATION AND
DISEASES
Given the known importance of lncRNAs in skeletal muscle
myogenesis, it is not surprising to know that they also regulate
the process of muscle regeneration. lncRNAs such as H19,
DUM, MUNC, Yam1 and lncMyoD have been shown to regulate
regeneration in cardiotoxin (CTX) model of muscle injury
(Shiekhattar, 2013; Dey et al., 2014; Gong et al., 2015; Mueller
et al., 2015; Wang L. et al., 2015). Upon CTX mediated injury, the
expression of H19 was decreased at days 1–3, followed by increase
at days 5–7 and again decreased after the formation of new
myofibers at day 14. Interestingly, miR-675-3p and miR-675-5p
are co-expressed with H19 throughout the course of regeneration,
making it evident that the pro-differentiation action of H19 is
mediated by microRNAs generated from it (Dey et al., 2014).
While H19 is implicated in regulating regeneration at several
stages, expression of Yam1 appears to be stage specific with
highest expression at day 2 followed by a sharp reduction for
the rest of the regeneration process (Lu et al., 2013). Likewise,
lncMyoD is upregulated at days 3–5 and decreased for the
remaining regeneration process (Gong et al., 2015). In contrast,
MUNC regulates late stage muscle regeneration as its knockdown
decreased the average diameter of myofiber at day 14 (Gong
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TABLE 1 | List of lncRNAs regulating skeletal muscle myogenesis and their regulatory mechanisms.
lncRNA Target Mechanism Function/disease relevance Species References
AK143003 Unknown Unknown Negative regulation of
differentiation
Mouse Guo et al., 2017
AK017368 Tnrc6a Sponge miR-30c Promotes myoblast proliferation Mouse Liang et al., 2018
Atrolnc1 NF-kb Murf-1 Decoy Promotes muscle wasting in
CKD mice
Mouse Sun et al., 2018
Charme Unknown Unknown Regulates robustness of
skeletal and cardiac
myogenesis.
In vivo depletion in mice
resulted in cardiomyopathy
Mouse Ballarino et al., 2018
Chronos Bmp7 Unknown Repressor of skeletal muscle
hypertrophy
Mouse Neppl et al., 2017
CERNA MyoD eRNA, regulate pol II occupancy
at MyoD
Promotes myogenesis Mouse Mousavi et al., 2013
DRR/MUNC MyoD, MyoG, Myh3 Cis and Trans regulation, Pol II
recruitment at myogenic
promoters
Promotes myogenesis And late
stage regeneration
Mouse, Human Mousavi et al., 2013;
Mueller et al., 2015
DBT-E Ash1l Guide chromatin remodeling at
D4Z4 locus
Expressed in FSHD patients Human Cabianca et al., 2012
Dum Dppa2 Cis, recruits Dnmt 1, 3a and 3b at
Dppa2 promoter
Promotes differentiation and
regeneration
Mouse Wang L. et al., 2015
H19 Let-7, Igf2, MyoD
miR-675, Sirt1/Foxo1
Cis and trans miRNA Sponge,
Precursor of miRNA
Promotes myogenic
differentiation
Mouse, Human
and Cattle
Wilkin et al., 2000;
Borensztein et al.,
2013; Kallen et al.,
2013; Dey et al.,
2014; Xu et al., 2017
lnc-31 Cyclins, Cdc25a Trans acting Maintenance of myoblast
proliferation, Upregulated in
mdx mice and DMD patient
myoblast
Mouse, Human Ballarino et al., 2015
linc-MD1 miR-133, miR-135, Hur
protein
Cis, miRNA sponge Controls time of muscle
differentiation, Reduced in DMD
patients
Mouse, Human Cesana et al., 2011
lnc-mg miR-125b miRNA sponge Promotes myogenesis,
Knockout and overexpression
resulted in atrophy and
hypertrophy in mice,
respectively
Mouse Zhu et al., 2017
lncMyoD IMP2 mediated mRNA
translation
Decoy Terminal muscle differentiation Mouse, Human Gong et al., 2015
lncMUMA miR-762 miRNA sponge Promotes differentiation,
protects against atrophy
Mouse, Human Zhang et al., 2018
linc-RAM Myogenic genes Scaffold, assembly of
MyoD-Baf60c-Brg1complex
Promotes differentiation,
Impaired muscle regeneration
in vivo knockout mice
Mouse Yu et al., 2017
linc-YY1 PRC2 Trans, Decoy Promotes differentiation,
impaired regeneration upon
knockdown
Mouse, Human Zhou et al., 2015
Malat1 miR-133, Myogenic
genes
miRNA sponge, Guide Suv39h1
to myoD binding loci
Promotes myogenesis,
Improved regeneration in
knockout mice
Mouse, Human Han et al., 2015;
Chen et al., 2017
MDNCR miR-133b miRNA sponge Promote differentiation Cattle Li H. et al., 2018
Myoparr MyoG Scaffold Promotes differentiation and
muscle
Mouse, Human Hitachi et al., 2019
Sirt1AS Sirt1 Cis-acting, protects Sirt1 mRNA
from miR-34a degradation
Promotes myoblast proliferation Mouse Wang G.-Q. et al.,
2016
SRA MyoD Unknown Promotes muscle differentiation Mouse Caretti et al., 2006
SYISL P21, myoG, Mck Guides EZH2 to promoter of
target genes
Promotes myoblast proliferation
and fusion
Mouse Jin et al., 2018
Yam 1 Wnt7b Cis-acting, Activates miR-715 Inhibits differentiation Mouse Lu et al., 2013
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et al., 2015; Mueller et al., 2015). Among others, the knockout of
linc-RAM and lncRNA IRM in mice displayed impaired muscle
regeneration, while the knockdown of MALAT1 enhanced the
regeneration (Chen et al., 2017; Yu et al., 2017; Sui et al.,
2019). Paradoxically, lncRNA LINC00961 encodes a conserved
polypeptide, SPAR, downregulated during the regeneration
process (Matsumoto et al., 2017). The downregulation of SPAR
activates mTORC1 important for skeletal muscle regeneration
and hypertrophy. The functional importance of SPAR emphasizes
that not all lncRNA-encoded peptides are translational noise and
also raises concern regarding the classification of lncRNAs.
Impaired regeneration process leads to conditions like atrophy
and hypertrophy characterized by muscle wasting and increase
in size of muscle cells, respectively. Cachexia is a condition
that involves atrophy and muscle wasting, commonly associated
with chronic kidney disease (CKD) (Morley et al., 2006).
lncRNA Atrolnc-1 is elevated in atrophic muscles of mice
with cachexia and its inhibition in mice with CKD attenuated
muscle wasting (Sun et al., 2018). Targeting Atrolnc-1 could
possibly help ameliorate the severity of CKD. lncMUMA was
also regulated during atrophy with minimum expression during
atrophy development in hindlimb suspension (HLS) mouse
model (Zhang et al., 2018). A study on the role of lncRNA in
age-associated atrophy identified lncRNA Chronos as a repressor
of hypertrophic growth through negative regulation of BMP7
(Neppl et al., 2017). The dysregulation of lncRNAs during
atrophy and hypertrophy further strengthens their importance in
development of muscle fibers.
Similar to atrophy and hypertrophy, lncRNA expression is
dysregulated in muscular dystrophy. DMD is the most prevalent
type of dystrophy caused by lack of functional dystrophin protein
that connects muscle fibers to extracellular matrix (Hoffman
et al., 1987). A study using tilling array designed for dystrophin
locus identified novel lncRNAs with expression profiles similar to
those of dystrophin gene (Bovolenta et al., 2012). These lncRNAs
have a repressive role on the full-length dystrophin isoform
and their expression is inversely correlated with dystrophin
long isoform in the muscle of female dystrophinopathy carriers.
Among other lncRNAs, lnc-31 is upregulated in mdx mice
muscle and human DMD patients (Ballarino et al., 2015). On
the contrary, linc-MD1 was reduced in DMD patients (Cesana
et al., 2011). Facioscapulohumeral muscular dystrophy (FSHD)
is another type of dystrophy characterized by wasting of facial,
upper arm and shoulder girdle muscle. In 95% of FSHD cases
the defect is a deletion in D4Z4 microsatellite repeat, leading
to loss of repressive mark (Wijmenga et al., 1990, 1992). This
de-repression is coordinated by a chromatin associated lncRNA
DBT-E transcribed from D4Z4 repeat through the recruitment
of Trithorax group protein at FSHD locus (Cabianca et al.,
2012). Although, a few lncRNAs have been reported and studied
in muscular dystrophies, they haven’t been studied in non-
dystrophic muscle diseases.
Given that lncRNAs are dysregulated in various muscular
diseases, they can possibly be novel biomarkers or targets for
therapeutic interventions. However, studies investigating
lncRNAs in patients with muscular diseases are much
languished. Genome wide association studies on different
cohorts of muscular disorders may help identify lncRNA loci
closely associated with genetic disorders. lncRNAs regulating
myogenesis has been well explored in in vitro and in vivo
mouse models, nonetheless their role in humans needs to be
investigated in depth.
lncRNAs IN CARDIOVASCULAR
DEVELOPMENT, PROLIFERATION AND
DIFFERENTIATION
The heart is the first organ to be formed during mammalian
embryogenesis. It consists of a multitude of cell types that
are formed through complex lineage commitment programs
acting upon lateral plate and paraxial mesoderm (Bruneau, 2013;
Stone and Stainier, 2019). The intricate network of signaling
pathways and the core transcriptional networks in cardiovascular
biology have been extensively investigated for many years.
On par with the skeletal muscle development and function,
lncRNA discovery has unraveled a new layer of regulation in
cardiac biology. A number of studies have identified several
lncRNAs crucial for cardiac commitment, differentiation and
dysfunction leading to diseased conditions. Many groups have
discovered new platforms to identify and catalog lncRNAs that
regulate cardiac commitment and pathologies (Grote et al., 2013;
Kumarswamy et al., 2014; Ounzain et al., 2014; Viereck et al.,
2016). Furthermore, the involvement of lncRNAs as therapeutic
targets for cardiovascular diseases (CVDs) is beginning to be
understood. In this section, we discuss the role of lncRNAs that
specifies and regulates the function of cardiomyocytes, smooth
muscle cells and endothelial cells and their roles in CVDs
and therapeutics.
lncRNAs REGULATING EARLY CARDIAC
FATE AND DISEASE
The minimal regenerative capacity of cardiomyocytes makes it
difficult to overcome the damage caused by cardiac diseases.
Hence, novel strategies are needed that can improve the
regenerative potential of the damaged myocardium. lncRNAs
have emerged as novel modulators in cardiac development
and regeneration in recent years. Braveheart (Bvht) is the
first lncRNA identified in mouse cardiac commitment and its
depletion in differentiating mouse embryonic stem cells (mESCs)
reduced the potential to form cardiac tissue (Klattenhoff et al.,
2013). More specifically, Bvht functions upstream of Mesp1,
a master regulator of cardiac differentiation and depletion of
Bvht decreased the expression of early cardiac cell surface
markers (such as PdgfRa and Flk-1) with consistent increase in
hematopoietic markers, suggesting its involvement in regulating
cell fate decisions (Klattenhoff et al., 2013). However, the role of
Bvht in hematopoietic differentiation is unclear and needs further
investigation. Bvht lacks a human ortholog and this loss in the due
course of evolution represents the species-specific differences in
heart development.
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lncRNA Fendrr with its expression restricted to the nascent
lateral plate mesoderm, regulates cardiac differentiation by
interacting with the PRC complex (Grote et al., 2013). Fendrr
is imperative for the development of the heart and the body
wall. Mechanistically, Fendrr binds to two major chromatin
modifiers, PRC2 and TrxG/MLL, and recruits these complexes to
the promoters of genes involved in inception and differentiation
of the lateral plate mesoderm, thus regulating cardiac lineage
commitment (Grote et al., 2013).
CARMEN, (CAR)diac (M)esoderm (E)nhancer-associated
(N)oncoding RNA) is a super enhancer (SE)-associated lncRNA
identified in the transcriptome of cardiac precursor cells (CPCs)
obtained from the human fetal heart (Ounzain et al., 2014,
2015). The CARMEN locus is upstream of two microRNAs
known to direct differentiation toward SMC—MiR-143 and -
145. CARMEN is a conserved lncRNA and shelters a highly
active, notch-repressive, SRF/NKX2.5 bound cardiac enhancer,
responsible for restricted expression of miR-143 and miR-145
during cardiac development. Notably, the mouse ortholog of
Carmen and previously mentioned lncRNA Bvht are co-located
in the mouse genome. Both of the lncRNAs showed maximum
expression between cardiac mesoderm and cardiac precursor
stages during induced cardiac differentiation of P19CL6 cells,
indicative of their involvement in early cardiac specification.
While Bvht works in trans, CARMEN functions in cis as well
as in trans and both were found to be essential for maintaining
the cardiac identity in neonatal cardiomyocytes (Klattenhoff
et al., 2013; Ounzain et al., 2015). Thus, CARMEN represents
a SE-associated lncRNA that can potentially be manipulated for
initiating neocardiogenesis for treating a heart damage.
Global transcriptomic profiling of enhancer transcribed
lncRNAs during ESC differentiation into cardiomyocytes in
mouse and human reveal co-expression of many of lncRNAs
and their predicted downstream targets (Ounzain et al., 2014).
The human enhancer transcripts of mm-67, -85, and -130
were significantly upregulated at different time points of
cardiac differentiation. More specifically, knockdown of mm-85
derived lncRNA in P19CL6 mouse embryonic carcinoma cells
significantly decreased myocardin expression and upregulated
mm-67 present within the myocardin gene (Ounzain et al., 2014).
This shows the crucial role of mm-85 in regulating myocardin
expression in mouse P19CL6 embryonic carcinoma cells.
The growing body of experimental evidence suggests that
enhancer derived lncRNAs are important for expression of
proximal target genes in cardiac development. lncRNA Uph (also
named Upperhand or Hand2os1) is transcribed from upstream
enhancer of HAND2, a regulator of heart development and
reprogramming of fibroblast to cardiomyocytes (Anderson et al.,
2016). Knockout of Uph in mouse embryos resulted in the
inability of the embryo to develop a right ventricular chamber and
the cardiac phenotype emulated by HAND2 knockout embryos
(Anderson et al., 2016). More recently, deletion of Uph in
the mouse upregulated the expression of Hand2 accompanied
by the dysregulated cardiac gene program, congenital heart
defects and prenatal lethality (Han et al., 2019). While Uph
is transcribed upstream, lncRNA Handsdown (Hdn) is located
downstream of Hand2 (Ritter et al., 2019). The genetic analysis
in mice demonstrated that Hdn is haploinsufficient and Hdn-
heterozygous mice presented right ventricular hyperplasia with
increased levels of Hand2 (Ritter et al., 2019). Thus, Uph and Hdn
regulate Hand2 expression in cis thereby playing a crucial role in
cardiac development.
A study in human ESCs and zebrafish developmental
models identified three lncRNAs implicated at different
stages of mesoderm and cardiovascular development, namely,
TERMINATOR, PUNISHER and ALIEN (Kurian et al., 2015).
These three lncRNAs are conserved from zebrafish to humans
and manifest similar stage-specific expression. TERMINATOR
is essential for early embryonic survival, pluripotency and early
mesendodermal differentiation. TERMINATOR knockdown in
zebrafish resulted in >70% lethal embryos, and developmental
arrest and severe cardiovascular defects in the surviving embryos
(Kurian et al., 2015). Mesodermal specification is marked by
the expression of ALIEN. Loss of ALIEN resulted in mesoderm-
related defects including defective vascular patterning and
cardiac chamber formation, alluding toward specific role of
ALIEN in the early developmental of the progenitor stage
common to vascular and cardiomyocyte fates. Silencing of
PUNISHER was also accompanied by severe impairments in
vasculature and cardiac development and function (Kurian et al.,
2015). These results were extrapolated to mouse embryos and
human ESCs by knockdown of the three lncRNAs followed by
microarray hybridization to check for the differential expression
of different genes at different stages upon knockdown of these
individual lncRNAs (Kurian et al., 2015). Albeit the mechanisms
employed by these lncRNAs in controlling the developmental
processes remains elusive.
lncRNA H19 besides its role in early embryonic development,
is also critical for late stage cardiac differentiation. During the
late stage cardiac differentiation of P19CL6 mouse cells, H19
knockdown promoted cell proliferation and inhibited apoptosis
(Han et al., 2016). H19 curbs the expression of miR-19b, thereby
increasing the expression of miR-19b target Sox-6. Thus, H19
presents a classic example of lncRNAs having tissue specific
roles and targets and provides an explanation for how lncRNAs
are capable of regulating a wide variety of cellular processes
at different stages in various tissues. Table 2 consolidates the
function of lncRNAs involved in cardiovascular development,
homeostasis and their relevance to CVDs.
With the expanding knowledge about the importance of
lncRNAs in cell fate decisions and heart development, it is
evident that they are operational in maintaining the homeostasis
of cardiovascular system. High throughput RNA-sequencing
has steered the identification of differentially regulated lncRNAs
in cardiac pathologies. One of the common heart conditions
is cardiac hypertrophy, characterized by the increase in
cardiomyocyte size to compensate for inappropriate cardiac
function leading to heart failure (HF). lncRNA CHAST was
upregulated in murine and human cardiac hypertrophy and
in vivo depletion of this lncRNA in mouse hypertrophic model
prevented and reverted the condition (Viereck et al., 2016).
CHAST promotes hypertrophy by blocking autophagy and
its inhibition prevented HF, thus presenting a promising
target for treatment. Chaer is another pro-hypertrophic
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TABLE 2 | List of lncRNAs with their regulatory mechanisms and physiological impact in cardiovascular biology.
lncRNA Target Mode of action Function Species References
ALIEN Unknown Unknown Cardiovascular commitment Human, Mouse
and Zebrafish
Kurian et al., 2015
ANRIL CDKN2A/B ADIPOR1,
VAMP3, C11ORF10
Scaffold Genetic risk factor for CAD
Pro-atherogenic
Human Bochenek et al.,
2013; Holdt et al.,
2013
Apf Atg7 Sponge miR-188-3p Controls autophagy and MI Mouse Wang K. et al., 2015
Bvht Hand1, Hand2, Mesp1,
Nkx2-5, Tbx20
Decoy Cardiac lineage commitment Mouse Klattenhoff et al.,
2013
Carl Pbh2, Bax, Caspase3,
Bcl-2
miR-539 sponging Inhibits mitochondrial fission and
apoptosis in cardiomyocyte
Mouse, Human
and Rat
Wang et al., 2014b;
Li L. et al., 2018
CARMEN Gata4, mesp1, Nkx2-5,
Myh6
Cis and trans regulation
SE-associated
Cardiac specification Mouse Human Ounzain et al., 2015
Chast Plekhm1 Cis-regulation Promotes hypertrophy Mouse, Human Viereck et al., 2016
Chaer Hypertrophy genes Guides PRC2 to
hypertrophic gene loci
Promotes hypertrophy Mouse, Human
and Rat
Wang Z. et al., 2016
Chrf Myd88 Sponge miR-489 Promote hypertrophy, Elevated in HF
tissues
Mouse, Human Wang et al., 2014a
Fendrr Foxf1, Gata6, Nkx2-5,
Pitx2
Guide PRC2 and TrxG/MLL
to promoters of target genes
Cardiovascular development Mouse, Human
and Rat
Grote et al., 2013
Ftx Bcl2l2 miR-29b-1-3p sponge Inhibits cardiomyocyte apoptosis Mouse Long et al., 2018
GAS5 ANNEXIN A2 Guide Supress SMC proliferation and
migration
Human Li et al., 2015
GATA6-AS LOXL2 Decoy Induced in ECs during hypoxia,
involved in EndMT
Human Neumann et al., 2018
H19 Sox6, MAPK, NF- kB,
PTEN, VCAM-1, p21,
TGF-β1
Sponge miR-19b, positively
regulates miR-675, inhibition
of phosphorylation of STAT3.
Proliferation and apoptosis during late
stage cardiac differentiation,
pro-atherogenic, promotes VSMC
proliferation and restenosis, negatively
regulates EC aging, prevents glucose
induced EndMT
Mouse, Human
and Rat
Han et al., 2016; Pan,
2017; Lv J. et al.,
2018; Hofmann et al.,
2019
MALAT1 TGFBR2/SMAD3, Cyc
or CCN A2, B1, B2,
Cdk1, ATG7
Sponge miR-145 EndMT, Controls proliferation and
migration of ECs
Human Michalik et al., 2014;
Song et al., 2018
LEENE eNOS eRNA, recruits Pol II at
eNOS promoter
EC homeostasis Human, Mouse Miao et al., 2018
MEG3 PTEN, AMPK and
JAK-STAT signalling
Sponge miR-21, sponge
miR-9
SMC proliferation and migration,
supress EC proliferation and
angiogenesis
Human He et al., 2017; Zhu
et al., 2018
Mdrl miR-484 miR-361 Regulates cardiomyocyte mitochondrial
fission and apoptosis
Mouse Wang et al., 2014c
MIAT VEGF Sponge miR-93 and
miR-150
Pro-hypertrophic Human, mouse Zhu et al., 2016; Li Y.
et al., 2018
Mm67/77/85/
130/132
Unknown Cis-regulation, eRNAs Cardiac development and remodelling Mouse Ounzain et al., 2014
Mhrt Brg1 Decoy Prevents hypertrophy and HF Mouse, Human Han et al., 2014
MYOSLID MYOCD, MRTF-A,
TGF-β (SMAD)
Cis and trans-regulation SMC differentiation and proliferation Human Zhao et al., 2016
linc-p21 P53 Mdm2 mediated
ubiquitination of p53
Repress VSMC proliferation and induce
apoptosis, downregulated in
atherosclerotic plaques in mice model
Human, Mouse Wu et al., 2014
SENCR MYOCD, CCL5,
CX3CL1, CDH5
Decoy SMC contractibility, potentiates
mesodermal and endothelial
commitment, regulates proliferation and
migration of ECs, stabilize EC adherens
junction, dysregulation associated with
premature CAD and limb ischemia
Human Bell et al., 2014;
Boulberdaa et al.,
2016; Lyu et al., 2019
(Continued)
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TABLE 2 | Continued
lncRNA Target Mode of action Function Species References
SMILR HAS2, CENPF Cis-acting SMC proliferation, Increased expression
in unstable atherosclerotic plaque and
in plasma of high plasm CRP
Human Ballantyne et al., 2016;
Mahmoud et al., 2019
RNCR3 KLF2 Sponge miR-185-5p Athero-protective Human Shan et al., 2016
ROR ANP and BNP Sponge miR-133 Pro-hypertrophic Mouse, Human Loewer et al., 2010
PANCR PITX2 Cis-acting Induced during early differentiation of
hESCs to cardiomyocytes
Human Gore-Panter et al., 2016
PLSR4 Mfn2 Sponge miR-214 Anti-hypertrophic Mouse Lv L. et al., 2018
PUNISHER FOXC1, TAL1 Guide Endothelial commitment Human, Mouse
and Zebrafish
Kurian et al., 2015
Upperhand Hand2 Cis-acting, eRNA Heart development Mouse Anderson et al., 2016
lncRNA which transiently interacts with PRC2 complex and
attenuates hypertrophy upon its silencing in pre-stressed heart
(Wang Z. et al., 2016). Unlike CHAST and Chaer, Mhrt is
a cardioprotective lncRNA regulated by the stress activated
Brg1-Hdac-Parp chromatin repressive complex (Han et al.,
2014). Pathological stress activates Brg1 leading to aberrant gene
expression including inhibition of Mhrt. Ultimately, this leads to
cardiomyopathy and hypertrophy (Hang et al., 2010; Han et al.,
2014). Mhrt forms a feedback loop with chromatin remodeling
factor Brg1 and its repression results in cardiomyopathy.
Restoring the pre-stress levels of Mhrt prevented hypertrophy
and heart failure. Human ortholog of lncRNA Mhrt is repressed
in various myopathic hearts demonstrating a conserved lncRNA
dependent mechanism in cardiomyopathy (Han et al., 2014).
These studies not only highlight the role of lncRNAs in diseases
but also emphasize their therapeutic potential.
lncRNAs REGULATING ENDOTHELIAL
CELL FUNCTION
New blood vessel formation is obviously an important aspect of
heart regeneration. In the adult body, perturbed vessel formation
may lead to inappropriate blood supply accompanied by shortage
of oxygen to the heart resulting in diseased conditions such as
myocardial infarction (MI). Endothelial cells (ECs) are important
for the formation of the blood vessels and EC dysfunction
is one of the early steps in the development of vascular
pathologies. Many studies have identified lncRNAs regulating
ECs function (Figure 4A) and lncRNAs differentially regulated
during vascular diseases. One such example is MALAT1 which
is elevated in TGF-β1-induced endothelial-to-mesenchymal
transition (EndMT) where it regulates TGFBR2 and SMAD3 by
negatively regulating miR-145 (Xiang et al., 2017). EndMT is
a hallmark of various pathological conditions including CVDs,
fibrosis and cancer and MALAT1 regulation of EndMT is a
potent target for the development of gene therapy approaches.
MALAT1 is also involved in the regulation of proliferation
of ECs. MALAT1 knockdown increased basal sprouting and
migration, inhibiting the proliferation. The reduced proliferation
was due to the switch of ECs from a proliferative to promigratory
phenotype. In addition, there was a simultaneous increase in
the expression of cell cycle inhibitors, such as p21 (Michalik
et al., 2014). Furthermore, Malat1 expression was elevated in
hypoxic conditions and its inhibition in a hind limb ischemia
mouse model showed reduced capillary density and blood flow
recovery (Michalik et al., 2014). Similarly, the inhibition of
lncRNA MANTIS also prevented the angiogenic sprouting and
alignment of ECs subjected to sheer stress (Leisegang et al., 2017).
MANTIS controls the angiogenesis by activating the ATPase
activity of BRG1, facilitating the assemblage of RNA polymerase
II onto key endothelial genes like SOX18, SMAD6, and COUP-
TFII (Leisegang et al., 2017). Unlike MALAT1 and MANTIS,
overexpression of lncRNA MEG3 suppressed EC proliferation
and in vitro angiogenesis through negative regulation of miR-9
(He et al., 2017).
Recently, Fiedler et al. (2015) generated an expression
atlas of human hypoxia-sensitive lncRNAs with identification
of two lncRNAs—LINC00323 and MIR503HG—important for
sustaining EC function. The expression levels of growth factor
signaling and endothelial TF GATA2 were alleviated upon
silencing of these two lncRNAs, accompanied by impaired cell
cycle control and blocked capillary formation (Fiedler et al.,
2015). Another study aiming to determine hypoxia influence
on lncRNA expression in HUVECs identified lncRNA GATA6-
AS to be upregulated during hypoxia (Neumann et al., 2018).
In vitro EndMT was reduced upon GATA6-AS silencing along
with impaired vascular sprouting and endothelial cell migration
(Neumann et al., 2018). Additionally, EndMT was regulated
by H19 during diabetic retinopathy where overexpression of
H19 prevented glucose mediated EndMT through regulation
of TGF-β1 signaling in a Smad-independent manner (Thomas
et al., 2019). Moreover, H19 was shown to regulate EC aging
via negative regulation of age induced inflammatory activation
(Hofmann et al., 2019).
lncRNA SENCR is important for endothelial cell commitment
and function. SENCR overexpression substantially enhanced the
mesodermal and endothelial commitment of hESC (Boulberdaa
et al., 2016). In HUVECs, the upregulation of SENCR
instigated migration, proliferation and formation of capillary-
like structures. Concomitantly, silencing of SENCR had reducing
effects on these processes. Known migratory and angiogenesis
genes were downregulated upon SENCR silencing, with no
effect on the expression of neighboring FLI1 gene. Vascular
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FIGURE 4 | lncRNAs regulating endothelial (EC) and smooth muscle cell (SMC) biology. (A) Examples of lncRNA regulating Endothelial cell identity, physiology and
activated in hypoxic conditions. (B) Examples of lncRNA regulating SMC proliferation, migration, contractibility and phenotypic modulation between contractile and
synthetic phenotype.
cells derived from patients with limb ischemia and premature
coronary artery disease (CAD) showed a reduced level of SENCR
as compared to control samples (Boulberdaa et al., 2016).
Recently, SENCR was found to be important for maintaining the
membrane integrity of ECs to control the vascular permeability
(Lyu et al., 2019). Another important aspect of EC biology is
Nitric Oxide synthesis (eNOS) that controls the vasodilation.
RNA-seq and chromatin capture study identified eRNA LEENE
enhancing the eNOS expression by recruiting RNA pol II to
the eNOS promoter (Miao et al., 2018). These results suggest
the importance of lncRNA in EC homeostasis and endothelial
dysfunction which is one of the key triggers of vascular diseases.
lncRNA IN VASCULAR SMOOTH
MUSCLE CELL (VSMC) FUNCTION
In addition to ECs, VSMC development and function is
important in vascular setting. In contrast to terminally
differentiated skeletal muscles, VSMCs can undergo reversible
phenotypic change between contractile and synthetic phenotypes
(Rensen et al., 2007; Davis-Dusenbery et al., 2011). The
phenotypic diversity of VSMCs provide the necessary flexibility
to the blood vessels to function under different physiological
(Figure 4B) and pathological conditions. In normal adult
animals, VSMCs exist as highly specialized and differentiated
cells with a contractile phenotype. During several vascular
pathologies the differentiated VSMCs switch to a proliferative
phenotype with surged synthetic activity (Iyemere et al., 2006).
Recent studies have identified lncRNA MALAT1 and a novel
lncRNA SMILR as important regulators of the switch from a
differentiated to a proliferative phenotype of VSMCs (Ballantyne
et al., 2016; Song et al., 2018; Mahmoud et al., 2019). Both were
shown to promote proliferation and migration of VSMCs, but
the mechanism employed and target genes are different for each.
MALAT1 knockdown facilitated the conversion of SMCs from
a proliferative phenotype to a differentiated one by inhibiting
autophagy (Song et al., 2018). Mechanistically MALAT1 was
found to compete with miR-142-3p to regulate ATG7 mediated
activation of autophagy that results in the conversion of VSMCs
from a contractile to a proliferative state. While MALAT1 acts in
trans, SMILR influences cellular proliferation by regulating the
expression of proximal gene HAS2, involved in atherosclerotic
lesion formation (Ballantyne et al., 2016). More specifically,
SMILR affects the late mitotic and cytokinesis phases of cell cycle
by interacting with CENPF and this SMILR:CENPF interaction is
in turn regulated by Staufen1 RNA binding proteins (Mahmoud
et al., 2019). Alteration of mature VSMC from a contractile
phenotype to an osteoblastic phenotype is another major aspect
of VSMC biology, which leads to vascular calcification (Iyemere
et al., 2006). The transcriptome analysis during calcification of
rat VSMCs identified lncRNA Lrrc75a-as1 as a negative regulator
of vascular calcification (Jeong et al., 2019).
Thirty one lncRNAs were identified from RNA-Seq in human
coronary artery SMCs (HCASMC), one of which was SENCR, that
helps maintain the normal SMC differentiated state (Bell et al.,
2014). SENCR is transcribed antisense to the Friend Leukemia
Integration virus1 (FLI) gene, whereas, SENCR knockdown
had no effect on the expression of FLI1 or other neighboring
genes ruling out cis-acting effects of SENCR on local gene
expression. Attenuation of SENCR significantly reduced the
expression of many SMC contractile genes, including MYOCD,
at both mRNA and protein levels with significant increase in
genes inducing motility (Bell et al., 2014). Collectively, these
results confirm the regulatory importance of SENCR in human
coronary artery SMC (HCASMC) differentiation and migration.
A study searching for lncRNAs regulated by myocardin
(MYOCD/SRF), the master switch for VSMC differentiation,
identified lncRNA MYOSLID (MYOcardin-induced Smooth
muscle Long non-coding RNA, Inducer of Differentiation) as
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a direct target for MYOCD/SRF and TGFβ/SMAD pathways
(Zhao et al., 2016). MYOSLID promoted VSMC differentiation
and inhibited VSMC proliferation. lncRNAs regulating SMC
phenotypic modulation, proliferation and migration might be
used as molecular targets in therapies for diseases aggravated by
vascular remodeling.
Excessive proliferation of VSMCs is a major attribute of
restenosis. In vitro overexpression of H19 accelerated VSMC
proliferation by positively regulating miR-675, which in turn
downregulates PTEN expression (Lv J. et al., 2018). H19
and miR-675 were upregulated in injured arterial walls in
a rat balloon injury model (Lv J. et al., 2018). lnc-GAS5 is
another lncRNA implicated in proliferation and migration of
SMCs. Overexpression of lnc-GAS5 inhibited the proliferation,
migration and reduced apoptosis of human saphenous vein SMCs
(HSVSMCs) and conversely, its silencing promoted these cellular
behaviors (Li et al., 2015). lnc-GAS5 function is mediated through
a Ca2+-dependent RNA binding protein, Annexin A2. Thus, low
expression of lnc-GAS5 increases proliferation and migration of
HSVSMCs through AnnexinA2 facilitating in the pathogenesis of
the Great Saphenous Veins. linc-p21 is also shown to regulate
SMC proliferation but its expression is downregulated during
atherosclerosis (Wu et al., 2014). linc-p21 silencing in a carotid
artery injury mouse model resulted in neonatal hyperplasia due
to dysregulation of multiple P53 targets (Wu et al., 2014). The
angiotensin II regulated lnc-Ang362 is a host for miR-221 and
miR-222, two known miRNAs implicated in SMC proliferation
(Leung et al., 2013). lnc-Ang362, miR-221 and miR-222 were
increased in the lung tissues derived from pulmonary arterial
hypertension (PAH) patients (Wang et al., 2019). Thus, lnc-
Ang362 could be a target for treating PAH.
DIAGNOSTIC POTENTIAL OF lncRNAs IN
CVDs
lncRNA with prognostic and diagnostic potential are of particular
interest in the clinical arena. A Genome wide association study
(GWAS) has identified chromosome 9p21 locus exhibiting the
highest association with atherosclerosis (Holdt et al., 2013).
This risk locus encodes for lncRNA ANRIL, associated with
atherosclerotic severity. Further investigations revealed that
ANRIL functions in trans, leading to pro-atherogenic effects
such as cell proliferation, increased cell adhesion and decreased
apoptosis (Holdt et al., 2013). The association of increased
ANRIL level with LV dysfunction further highlights its diagnostic
and prognostic importance. Similarly, another GWAS study
identified that the single nucleotide polymorphism (SNP)
associated with MI altered the expression of lncRNA MIAT
(Ishii et al., 2006).
Circulating lncRNAs can serve as biomarkers of the diseases
making the diagnosis much easier. A transcriptome study
identified lncRNA LIPCAR in the plasma of patients with heart
failure as a novel biomarker which can predict heart remodeling
and future death in the patients (Kumarswamy et al., 2014).
Another study performed the microarray analysis in the plasma
of CAD patients and reported that lncRNA CoroMarker as
a sensitive biomarker for CAD (Yang et al., 2015). Likewise,
circulating ZFAS1 and CDR1AS were found to be decreased
and increased in acute myocardial infarction (AMI), respectively
(Zhang et al., 2016). Another study reported low levels of lncRNA
GAS5 in the plasma of 30 CAD patients as compared to 30 healthy
individuals (Yin et al., 2017).
Promising results for several kinds of lncRNAs were
reported similarly (Schlosser et al., 2016). However, the authors
observed difficulties in reproducibility of detection. This could
be due to the low sensitivity of the conventional lncRNA
detection methods. Regardless of the technical challenges the
low abundancy of lncRNAs cannot undermine their reported
functional importance in many instances highlighted in this
review. A summary of lncRNAs as potential biomarkers and their
roles in cardiac diseases is represented in Figure 5.
lncRNA–miRNA INTERACTIONS IN
SKELETAL MUSCLE AND
CARDIOVASCULAR DEVELOPMENT
AND DISEASE
The crosstalk between lncRNA–miRNA–mRNA appears to be
common in different facets discussed so forth. lncRNAs inhibit
the function of miRNA by binding to them in a sequence
specific manner, thereby increasing the number of target mRNAs
that would otherwise be suppressed by miRNAs. In this regard,
comprehensive knowledge of complex lncRNA–miRNA–mRNA-
networks would help develop novel RNA-based therapeutics for
different diseases (Figure 6).
As seen in skeletal muscle proliferation and differentiation,
lncRNA H19, linc-MD1, lnc-mg and Malat1 inhibit the action
of miRNAs by the sponging mechanism (Cesana et al., 2011;
Kallen et al., 2013; Han et al., 2015; Chen et al., 2017; Zhu
et al., 2017). However, lncRNAs can regulate the function of
miRNAs in many different ways. For instance, lncRNA Sirt1As
shields the miR-34a binding site on Sirt1 mRNA by binding
to the transcripts (Wang G.-Q. et al., 2016). lncRNAs can
positively regulate miRNAs by acting as precursor miRNAs as
in the case of H19 giving rise to miR-675-3p and miR-675-5p
(Dey et al., 2014).
These RNA networks are not restricted to skeletal muscle
but are also noticeable in cardiovascular physiology and disease.
CHRF, Plscr4, MIAT and ROR were involved in miRNA
mediated cardiac hypertrophy regulation. lncRNA CHRF triggers
cardiomyocyte hypertrophy by sponging antihypertrophic miR-
489, which targets Myd88 (Wang et al., 2014a). Similarly,
pro-hypertrophic lncRNA MIAT regulates anti-hypertrophic
miR-93 and miR-150 (Zhu et al., 2016; Li Y. et al., 2018).
ROR is another hypertrophic inducer that sponges miR-
133 (Jiang et al., 2016). In contrast, Plscr4 is an anti-
hypertrophic lncRNA downregulating miR-214 to promote
the expression of Mfn2 (Lv L. et al., 2018). Apoptosis and
autophagy are among other pathways targeted by competing-
endogenous RNAs (ceRNAs). lncRNA CARL has been proposed
to inhibit cardiomyocyte apoptosis by sequestering miR-539,
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a microRNA targeting PHB2 (Wang et al., 2014b), a subunit
of mitochondrial membrane protein Prohibitin involved in
mitochondrial homeostasis (Tatsuta et al., 2005). Cardiomyocyte
apoptosis and mitochondrial fission was also inhibited by Mdrl
via downregulation of miR-361, counteracting the inhibition
of miR-484 processing (Wang et al., 2014c). lncRNA Ftx
inhibited cardiomyocyte apoptosis by preventing miR-29b-1-
5p mediated downregulation of Bcl2 (Long et al., 2018).
Likewise, Apf triggers autophagy by targeting Atg7 through
negative regulation of miR-188-3p, an inhibitor of autophagy and
myocardial infarction (Wang K. et al., 2015). It is interesting
to note that some of the above mentioned networks are well
conserved across species, suggesting the crucial roles, they have
in cardiovascular biology. Hence, modulating lncRNA-miRNA-
mRNA pathways could possibly be a novel strategy to suppress
cardiomyocyte loss in order to protect against myocardial
infarction (MI) and tailor therapies for hypertrophy. Thorough
understanding of these networks in development and disease
linc-MD1 miR-133 miR-135
lnc-mg miR-125b
AK017368 miR-30c
Sirt1AS miR-34a
Malat1 miR-133
MDNCR miR-133a
H19 miR-let7
miR-675-3p
miR-675-5pH19
Yam1 miR-715
MALAT1 miR-l45miR-142-3p
miR-19bH19
MEG3 miR-9
Carl miR-539
Chrf miR-489
MIAT
miR-93
miR-150
Plscr4 miR-214
Apf miR-188-3p
Mdrl miR-484
ROR miR-133
Nrf miR-873
Cardiac homeostasis 
and pathology
Skeletal muscle 
myogenesis
FIGURE 6 | Overview of lncRNA–miRNA interactions in skeletal muscle and
cardiovascular development and disease.
could help design better therapeutic strategies in the field of
regenerative medicine.
lncRNA THERAPEUTICS AND
CHALLENGES
There has been an increased interest in the understanding of
lncRNA regulation in disease systems due to their relatively
restricted expression patterns and different possible actions on
cellular function(s). Given that several of these ncRNAs are
dysregulated in disease conditions, modulating the levels of such
lncRNAs appears to be a promising approach for therapeutics
and preclinical testing. However, only a few lncRNAs have
been studied in depth in relevant ex vivo and in vivo systems.
Upregulation or downregulation/inhibition of lncRNA function
has been the most rigorously adopted methods to understand
their therapeutic potential in muscular defects and cardiovascular
damage. The most commonly used gene delivery methods for
RNA based therapeutics are recombinant viral systems such
as adenovirus, lentivirus and adeno-associated viruses (AAVs),
which are employed either to inhibit or to overexpress the mRNA,
miRNA, lncRNA whole transcripts (Eulalio et al., 2012; Gomes
et al., 2017; Gabisonia et al., 2019). The use of RNAi and antisense
oligonucleotides (ASOs) present the most commonly used
approaches for selective downregulation of potential lncRNAs.
On the contrary, the upregulation of lncRNAs can be achieved
by viral vectors that are very efficient for muscle delivery.
Using the above mentioned strategies, there have been promising
results toward miRNA targeting and protein coding transcripts in
preclinical systems, which reached clinical trials. However, using
the same delivery methods the therapeutic relevance of lncRNAs
remain to be resolved.
The siRNA mediated pharmacological inhibition of
cytoplasmic lncRNA SMILR in the ex vivo vein graft model
significantly reduced the SMC proliferation to ameliorate the
effects of vascular remodeling (Mahmoud et al., 2019). In
another approach using nanoparticle mediated transfection
of siRNA against lncRNA Chaer directly into mouse heart
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FIGURE 7 | lncRNA based diagnostics and therapeutic strategies. (A) Genome wide association studies (GWAS) help in the identification of lncRNA single
nucleotide polymorphisms (SNPs) associated with disease susceptibility. These SNPs can alter the lncRNA expression in the body fluids or tissues which can serve
as diagnostic or prognostic markers. In addition, improvements in RNA-sequencing technologies can lead to the identification of lncRNAs as biomarkers/disease
targets in different diseases. (B) (i) Summarizes the potential approaches for lncRNA therapeutics, such as siRNAs that are associated with RNA-induced silencing
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expression. (B) (ii) Demonstrates the different lncRNA delivery strategies such as direct injections, viral particles, or via encapsulation in nanoparticles.
decreased the cardiac hypertrophy and fibrosis and restored
cardiac function (Wang Z. et al., 2016). The inhibition level
achieved by shRNAs and siRNAs are, in general, limited to
the cytoplasmic lncRNA molecules. Hence, on the other hand,
ASOs or GapmeRs are more suitable for nuclear lncRNAs that
direct Dicer independent degradation of the target lncRNA by
RNase H activity (Fluiter et al., 2009; Bennett and Swayze, 2010;
Lennox and Behlke, 2016). The ASO technology has fewer off
target effects than the small RNA mediated approach. One such
example is GapmeR mediated inhibition of lncRNA Chast for
the prevention and regression of cardiac hypertrophy in vivo
(Viereck et al., 2016). No noticeable side effects of GapmeR
treatment were reported. In another study, GapmeR mediated
knockdown of Malat1 in mice muscle resulted in poor blood
flow recovery and diminished capillary density (Michalik et al.,
2014). In addition, in vivo therapeutic intervention using
GapmeRs targeting lncRNA Wisper suppressed cardiac fibrosis
and improved function (Micheletti et al., 2017). So far, none of
the antisense based lncRNA drugs have been tested in clinical
studies but, this strategy has been proven to be effective and
safe in a clinical trial targeting liver miR-122 with LNA-based
antimiRs (mirvarsen) (Zumla et al., 2013). The newer generation
of ASOs provide spatial control for target delivery and with
further improvements, this could be translated for lncRNA
inhibition in future clinical trials.
In comparison to inhibition, overexpression of
cardioprotective lncRNAs appear to be much more challenging
attributing to their length and locus complexity, and sometimes
incomplete knowledge of the complete sequence identity and
isoform structure in the current genome annotation. In this
context, the major challenge is efficient transportation of these
large transcripts across the membrane barriers and determining
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the potential toxicity. The transgenic gene activation of
the cardioprotective lncRNA Mhrt demonstrates the first
overexpression study highlighting the translational importance
of delivery of lncRNA as a drug (Han et al., 2014). In another
example, Chast overexpression using AAV9 (adeno-associated-
virus serotype 9) viral particles promoted cardiac hypertrophy
in mouse heart, suggesting it to be a crucial target for cardiac
hypertrophy (Viereck et al., 2016).
Advancements in RNA-sequencing technologies have led
to the identification of several lncRNAs in different diseases
suggesting them to be crucial targets for therapeutics. In
addition, due to their distinct expression patterns they can be
powerful tools for diagnostics, personalized medicine and drug
development. A brief description of lncRNA-based diagnostic
and therapeutic strategies is depicted in Figure 7. There are
several key challenges in any lncRNA-focused therapy. Firstly, the
lncRNAs due to their pleiotropic actions regulate multiple targets
and hence may not be target-specific and can act via more than
one mechanism in a diseased state. In addition, low conservation
of lncRNAs across species, is another challenge, for example a
human specific lncRNA lacking conservation in mouse, makes its
preclinical testing inappropriate (Lu and Thum, 2019). A further
challenge in lncRNA therapeutics is the fact that lncRNAs are
often integrated in complexes which make them inaccessible
for access. Small molecules such as aptamers may help the
lncRNA binding with the interacting protein complexes or induce
conformational changes in the secondary or tertiary structures of
lncRNA (Lunse et al., 2010). This is mainly important, where the
lncRNA expression does not attribute to the disease phenotype
but, the lncRNA interaction with other molecules accounts
for the disease. Hence, the secondary and tertiary structure of
lncRNAs and their structure-function relationship should to be
resolved before lncRNAs enter into therapeutics.
The other translational limitations of lncRNA therapeutics
is the lack of efficient and safe delivery systems for a
controlled and targeted release. The delivery vehicle should
ensure high transfection efficiency with minimal cytotoxicity
but also controlled release of the lncRNA based drug during
the complete process. lncRNA levels can be manipulated using
viral vectors, however, the use of viral delivery methods is
restricted due to the associated issues including off-target effects,
activation of host immune response and the risk of insertional
mutagenesis, although clinical evidence in gene therapy to date
demonstrates a favorable situation. To overcome these risks,
researchers believe non-viral vectors with chemical modifications
and/or nanoparticles targeted to specific cell type would be
advantageous in clinical trials, however, are relatively inefficient
dampening down the possibility for clear efficacy signals. Finally,
the use of gene editing technique such as CRISPR/Cas9 has
provided both loss- or gain-of-function of lncRNA in in vitro and
in vivo studies (Aparicio-Prat et al., 2015; Leisegang et al., 2017;
Ballarino et al., 2018). Although, similar delivery issues need to
be addressed with the use of gene editing tools in vivo too.
CONCLUSION
Several lncRNAs have been identified to be involved in
development and pathophysiology by regulating gene expression
at DNA, RNA and protein levels. Their specific expression
during differentiation and disease helps qualify them as key
regulators and potential therapeutic targets. However, at present
the use of lncRNAs in therapeutics is in its inception. There
are still certain technical issues that need to be addressed, such
as the difficulties in targeting, accurate outcome predictions
and discrepancies in knockdown phenotypes in in vitro and
in vivo. Further improvement in detection, silencing approaches,
mechanistic understanding and development of in vivo models
would uncover the full potential of lncRNAs as diagnostic and
possibly therapeutic targets.
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